Equillium (EQ) Projected to Post Earnings on Wednesday

Equillium (NASDAQ:EQ) is projected to post its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Equillium to post earnings of ($0.04) per share for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Equillium (NASDAQ:EQ) last issued its earnings results on Wednesday, March 25th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. On average, analysts expect Equillium to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Equillium Trading Down 1.4%

Shares of NASDAQ EQ opened at $2.07 on Wednesday. The company has a market cap of $130.89 million, a price-to-earnings ratio of -4.14 and a beta of 1.67. Equillium has a 12 month low of $0.27 and a 12 month high of $2.70. The stock has a 50-day moving average price of $1.99 and a two-hundred day moving average price of $1.52.

Insider Activity

In other news, COO Christine Zedelmayer sold 185,937 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $1.76, for a total value of $327,249.12. Following the completion of the transaction, the chief operating officer owned 191,444 shares of the company’s stock, valued at $336,941.44. This represents a 49.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 487,468 shares of company stock valued at $990,467 over the last three months. Corporate insiders own 17.84% of the company’s stock.

Institutional Trading of Equillium

Several institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC bought a new stake in Equillium in the fourth quarter valued at approximately $9,057,000. ADAR1 Capital Management LLC boosted its holdings in Equillium by 0.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company’s stock valued at $8,693,000 after acquiring an additional 48,090 shares during the last quarter. Woodline Partners LP bought a new stake in Equillium in the third quarter valued at approximately $5,018,000. Balyasny Asset Management L.P. boosted its holdings in Equillium by 3.6% in the fourth quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company’s stock valued at $3,218,000 after acquiring an additional 72,602 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Equillium by 59.4% in the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock valued at $1,879,000 after acquiring an additional 489,855 shares during the last quarter. 27.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the company. Cantor Fitzgerald assumed coverage on Equillium in a research note on Tuesday, April 7th. They set an “overweight” rating and a $10.00 target price for the company. Raymond James Financial assumed coverage on Equillium in a research note on Monday, April 13th. They set a “strong-buy” rating and a $6.00 target price for the company. Zacks Research raised Equillium to a “hold” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Equillium in a research note on Friday, March 27th. Finally, Oppenheimer assumed coverage on Equillium in a research note on Thursday, April 23rd. They set an “outperform” rating and a $7.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Equillium presently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.